Rank #1822AUPH

Aurinia Pharmaceuticals Inc

$14.40

0.63% (Daily)

Market Cap

$1.90B

Revenue

$265.81M

Rank by MCap

#1822

Sector

Healthcare

Industry

Biotechnology

CEO

Mr. Peter S. Greenleaf M.B.A.

Headquarters

Edmonton, AB

Employees

130

About Aurinia Pharmaceuticals Inc

Aurinia Pharmaceuticals Inc. is a biopharmaceutical company that engages in delivering therapies to people living with autoimmune diseases with high unmet medical needs. It offers LUPKYNIS (voclosporin), an oral therapy for the treatment of adult patients with active lupus nephritis. The company also develops AUR200, a dual inhibitor of B cell activating factor and a proliferation inducing ligand for the potential treatment of autoimmune diseases. It has a collaboration and license agreement ...